

UCSF Gram-negative Location-specific Weighted-incidence Combination Antibigram, 2017-2020

Parnassus, Adults, Inpatient Locations, All Culture Sites, Repeat Isolates Excluded, Cumulative 2017-2020

Ordering Location	CTRX	CTRX- PsA	ERTA	ERTA- PsA	PIP/TAZ	+CIP	CFP	+CIP	MER	+CIP
						+TOB		+TOB		+TOB
Emergency Department N~3700	78% (76-79%)	83% (82-84%)	89% (88-90%)	95% (94-96%)	95% (95-96%)	98%	90% (89-91%)	93%	98% (97-98%)	99%
						98%		94%		99%
Floor Patients N~2500	62% (60-63%)	73% (71-74%)	76% (75-78%)	86% (86-89%)	88% (86-89%)	93%	83% (81-84%)	87%	94% (93-95%)	95%
						94%		89%		96%
ICUs (Combined) N~1250	60% (57-63%)	72% (69-75%)	70% (68-73%)	84% (82-86%)	81% (79-83%)	91%	83% (81-85%)	88%	90% (88-92%)	93%
						92%		89%		94%
9 ICU N ~230	53% (47-60%)	69% (62-76%)	60% (54-67%)	77% (71-83%)	76% (70-81%)	88%	80% (75-85%)	86%	87% (82-91%)	92%
						89%		88%		93%
10 ICU N~250	57% (50-53%)	67% (60-73%)	66% (60-71%)	77% (71%-83%)	75% (69-79%)	86%	79% (74-84%)	84%	85% (80-89%)	89%
						88%		86%		90%
8 + 11 ICU N~450	71% (67-75%)	82% (78-86%)	79% (76-83%)	92% (89-94%)	91% (88-93%)	96%	91% (88-93%)	94%	96% (94-98%)	97%
						96%		94%		97%
13 ICU N~225	51% (44-58%)	63% (55-70%)	67% (61-73%)	83% (76-88%)	72% (66-78%)	88%	76% (70-81%)	82%	86% (80-90%)	89%
						90%		84%		92%

(-) = 95% CI on proportion; CTRX=ceftriaxone; ERTA=ertapenem; PIP/TAZ=piperacillin/tazobactam; CFP=cefepime; MER=meropenem; CTZ/AVI=ceftazidime/avibactam; -PsA=coverage excluding *Pseudomonas aeruginosa* isolates; +CIP=aggregate coverage when ciprofloxacin combined with adjacent beta-lactam; +TOB=aggregate coverage when tobramycin combined with adjacent beta-lactam